Vistin Pharma ASA

OB:VISTN Stock Report

Market Cap: kr1.0b

Vistin Pharma Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Magnus Tolleshaug

Chief executive officer

kr2.2m

Total compensation

CEO salary percentage81.0%
CEO tenure2.3yrs
CEO ownership0.2%
Management average tenureno data
Board average tenure6yrs

Recent management updates

Recent updates

Would Vistin Pharma (OB:VISTN) Be Better Off With Less Debt?

Feb 23
Would Vistin Pharma (OB:VISTN) Be Better Off With Less Debt?

A Look At The Fair Value Of Vistin Pharma ASA (OB:VISTN)

Sep 09
A Look At The Fair Value Of Vistin Pharma ASA (OB:VISTN)

Robust Earnings May Not Tell The Whole Story For Vistin Pharma (OB:VISTN)

Aug 25
Robust Earnings May Not Tell The Whole Story For Vistin Pharma (OB:VISTN)

Investors In Vistin Pharma ASA (OB:VISTN) Should Consider This, First

Mar 15
Investors In Vistin Pharma ASA (OB:VISTN) Should Consider This, First

We're Keeping An Eye On Vistin Pharma's (OB:VISTN) Cash Burn Rate

Feb 20
We're Keeping An Eye On Vistin Pharma's (OB:VISTN) Cash Burn Rate

Could The Vistin Pharma ASA (OB:VISTN) Ownership Structure Tell Us Something Useful?

Jan 29
Could The Vistin Pharma ASA (OB:VISTN) Ownership Structure Tell Us Something Useful?

The Vistin Pharma (OB:VISTN) Share Price Is Up 119% And Shareholders Are Boasting About It

Jan 08
The Vistin Pharma (OB:VISTN) Share Price Is Up 119% And Shareholders Are Boasting About It

Have Insiders Been Selling Vistin Pharma ASA (OB:VISTN) Shares?

Dec 16
Have Insiders Been Selling Vistin Pharma ASA (OB:VISTN) Shares?

Is Vistin Pharma ASA (OB:VISTIN) At Risk Of Cutting Its Dividend?

Nov 26
Is Vistin Pharma ASA (OB:VISTIN) At Risk Of Cutting Its Dividend?

CEO Compensation Analysis

How has Magnus Tolleshaug's remuneration changed compared to Vistin Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2024n/an/a

kr56m

Dec 31 2023kr2mkr2m

kr46m

Sep 30 2023n/an/a

kr45m

Jun 30 2023n/an/a

kr14m

Mar 31 2023n/an/a

kr7m

Dec 31 2022kr3mkr2m

-kr5m

Sep 30 2022n/an/a

-kr15m

Jun 30 2022n/an/a

-kr7m

Mar 31 2022n/an/a

kr929k

Dec 31 2021kr2mkr1m

kr25m

Sep 30 2021n/an/a

kr26m

Jun 30 2021n/an/a

kr30m

Mar 31 2021n/an/a

kr43m

Dec 31 2020kr2mkr1m

-kr97m

Compensation vs Market: Magnus's total compensation ($USD205.91K) is below average for companies of similar size in the Norwegian market ($USD322.94K).

Compensation vs Earnings: Magnus's compensation has been consistent with company performance over the past year.

CEO

Magnus Tolleshaug

2.3yrs

Tenure

kr2,238,000

Compensation

Mr. Magnus Tolleshaug Serves as a Commercial Director at Vistin Pharma ASA and served as its Interim Chief Executive Officer since February 16, 2022 until January 1, 2024 and serves as its Chief Executive...

Board Members

NamePositionTenureCompensationOwnership
Oyvin Broymer
Independent Chairman of the Board3.9yrskr441.00kno data
Oystein Spetalen
Independent Director9.3yrskr210.00k2.5%
NOK 25.8m
Bettina Banoun
Independent Director6yrskr231.00kno data
Kari Krogstad
Independent Director3.9yrskr210.00kno data
Åse Musum
Employee Representative Director9.3yrskr210.00k0.0050%
NOK 51.2k
Espen Marcussen
Independent Director4yrskr210.00kno data
Espen Gregoriussen
Employee Representative Director6.6yrskr210.00kno data

6.0yrs

Average Tenure

60yo

Average Age

Experienced Board: VISTN's board of directors are considered experienced (6 years average tenure).

Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.